Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28277684 | 0.91 | PARP1 (0.43) | PARP1MAP2K2MAP2K1NPC1MAPT | |
| SCHEMBL15066436 | 0.83 | PARP1 (0.44) | PARP1CSNK2A1MAP2K2MAP2K1CDC7 | |
| SCHEMBL11341497 | 0.81 | CSNK2A1 (0.45) | CSNK2A1MAPTHTTMEN1KMT2A | |
| SCHEMBL31695396 | 0.81 | CSNK2A1 (0.61) | CSNK2A1MAPTHTTMEN1KMT2A | |
| SCHEMBL1421936 | 0.81 | CSNK2A1 (0.61) | CSNK2A1MAPTHTTMEN1KMT2A | |
| SCHEMBL28277672 | 0.80 | PARP1 (0.43) | PARP1NPC1MAPTMEN1KMT2A | |
| SCHEMBL9380353 | 0.79 | CSNK2A1 (0.59) | CSNK2A1MAPTHTTMEN1KMT2A | |
| SCHEMBL8123981 | 0.79 | CSNK2A1 (0.44) | CSNK2A1NPC1MAPTMAPK1HTT | |
| SCHEMBL31373249 | 0.78 | MAP2K2 (0.41) | PARP1MAP2K2MAP2K1MAPTMAPK1 | |
| SCHEMBL1003845 | 0.78 | MEN1 (0.53) | PARP1CSNK2A1NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105294597-B | Benzothiazine derivatives and its synthetic method and application | 华东师范大学 | 2017-11-24 | — | — | CN | claimed |
| CN-105294597-A | Benzothiazine derivative, and synthetic method and application thereof | UNIV EAST CHINA NORMAL | 2016-02-03 | — | — | CN | claimed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-116535344-B | Phthalimide preparation method of class compound | 华南理工大学 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-116535344-A | Preparation method of phthalimide compound | 华南理工大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-105294597-B | Benzothiazine derivatives and its synthetic method and application | 华东师范大学 | 2017-11-24 | — | — | CN | disclosed |
| CN-105294597-A | Benzothiazine derivative, and synthetic method and application thereof | UNIV EAST CHINA NORMAL | 2016-02-03 | — | — | CN | disclosed |
| CN-105289663-A | Magnetically-recoverable GO/Fe3O4-CuI catalyst and preparation method and application thereof | UNIV TONGJI | 2016-02-03 | — | — | CN | disclosed |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-6919322-B2 | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| CN-1599612-A | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2005-03-23 | — | — | CN | disclosed |
| CN-1516705-A | Novel arylfructose-1, 6-bisphosphatase inhibitors | ֢�����ƹ�˾ | 2004-07-28 | — | — | CN | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | PARP1 3226/4885CSNK2A1 2870/4885MAP2K2 2660/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | PARP1 3226/4885CSNK2A1 2870/4885MAP2K2 2660/4885 |
| US-20020040014-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | FBP1, SLC5A1, G6PC1 | PARP1 2761/4885CSNK2A1 3282/4885MAP2K2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.